Toggle light / dark theme

Civilian Space Development has kicked-off: the work begins now!

Newsletter 17.09.2021 by Bernard Foing & Adriano V. Autino

During the last months we have seen the first civilian passengers fly to space, onboard Blue Origin and Virgin Galactic vehicles. September 15th, four civilian astronauts, onboard a Space X Dragon capsule, passed the 500 km orbit, more than 100 km higher than the ISS.In 2016 we started to publicly talk about and promote Civilian Space Development, while the whole space community kept on talking only about space exploration. Earlier, in 2,008 we founded the Space Renaissance movement, and a couple of years later the Space Renaissance International, as a philosophical association targeted to complete the Kopernican Revolution, supporting the Civilization expansion into space. Nowadays the concept of civilian space flight is everywhere on the media, and many people in the space community talk about a space renaissance. Of course the Coronavirus pandemics accelerated the awareness of the urgency to expand humanity into outer space. And space tourism — the first stage of civilian space settlement — is now a reality, in its first steps.

Of course nobody could be more happy than ourselves, for the above development, and of course**2 we want to congratulate with Elon, Richard and Jeff, for such a great achievement!

So, may we consider that our mission has been completed? Let’s see.

Firstly, were those crews composed by regular travelers, like normal air-flight passengers? Not exactly. The Inspiration4 crew members received astronaut training, for many months, including lessons in orbital mechanics, operating in a microgravity, stress testing, emergency preparedness training, and mission simulations. They have studied over 90 different kinds of training guides and manuals and lessons to learn to fly Crew Dragon, and what to do under emergency situations. The legal aspects are not clear: did FAA quickly authorize Space X and Blue Origin to deal commercial space flights? Doubt is more than legitimate, considering the long procedure followed by Virgin Galactic to be authorized to transport paying passengers in space. Likely, these first “civilian” passengers — like the first orbital tourist Dennis Tito did in 2001 — accepted conditions similar to the military astronauts (i.e. zero rights and warrants).

“Ronapreve has been shown to improve survival in high-risk, non-hospitalised COVID-19 patients by reducing the risk of hospitalisation and death. In addition, its ability to retain activity against emerging variants, including the Delta variant, has been demonstrated in preclinical studies,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “Today’s approval brings hope to patients in Japan who can now access this important treatment option.”


Japan becomes first country to approve Ronapreve (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19 in adults and paediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19 and/or hospitalisation. The US EUA is temporary and does not take the place of the formal biologics license application (BLA) submission, review and approval process.

The future of vaccines may look more like eating a salad than getting a shot in the arm. UC Riverside scientists are studying whether they can turn edible plants like lettuce into mRNA vaccine factories.

One of the challenges with this new technology is that it must be kept cold to maintain stability during transport and storage. If this new project is successful, plant-based mRNA vaccines — which can be eaten — could overcome this challenge with the ability to be stored at room temperature.

The project’s goals, made possible by a $500,000 grant from the National Science Foundation, are threefold: showing that DNA containing the mRNA vaccines can be successfully delivered into the part of plant cells where it will replicate, demonstrating the plants can produce enough mRNA to rival a traditional shot, and finally, determining the right dosage.

Watch the full documentary on Vimeo on demand: https://vimeo.com/ondemand/339083

The study of consciousness needs to be lifted out of the mysticism that has dominated it. Consciousness is not just a matter of philosophy or spirituality. It’s a matter of hard science. It’s a matter of understanding the brain and the mind — a pattern structure made out of information. It’s also a matter of engineering. If we can understand the functionality of the brain, its neural code, then we can build the same functionality into our computer systems. There’s no consensus on what produces consciousness, but everyone regardless of metaphysical views can agree what it is like to be conscious. Given that consciousness is subjectivity, what consciousness is like is what consciousness is.

‘Mind’ and ‘Consciousness’ are two different but somewhat overlapping terms related to the phenomenality of our experiential reality. Different species have a variety of their biological information processors which unsurprisingly results in qualia diversity. All species live in their own unique sensory universes. There is “something it is like to be” an organism. The human brain, our biological “wetware,” has a fractal structure on many genetic and abstract cognitive levels. Information is “modus operandi” of consciousness.

If we are to reason for the non-dual picture of the world then quantum physics is directly linked to consciousness. The human brain is a physical organ that transmits and interprets electrochemical signals. Its biochemistry is certainly governed by quantum physical laws, and consciousness — which is clearly related to the functioning of the brain — must therefore be related to the quantum physical processes going on within the brain and in the cosmos at large. Research has shown that consciousness is non-local, a scientific way of alluding to a connection within a higher dimensional order. Matter has also been shown to be non-local, which hints that matter might be an expression of consciousness, emerging from the ‘Unified Field’ — the quantum layer of pure potentiality — the code layer beneath all dimensions where time and space are information.

Molnupiravir, a wide-spectrum antiviral that is currently in phase 2/3 clinical trials for the treatment of COVID-19, is proposed to inhibit viral replication by a mechanism known as ‘lethal mutagenesis’. Two recently published studies reveal the biochemical and structural bases of how molnupiravir disrupts the fidelity of SARS-CoV-2 genome replication and prevents viral propagation by fostering error accumulation in a process referred to as ‘error catastrophe’.

Pfizer Inc (PFE.N) said on Thursday it was recalling all lots of its anti-smoking treatment, Chantix, due to high levels of cancer-causing agents called nitrosamines in the pills.

The drugmaker paused distribution of the drug in June, and has already recalled a number of lots of the medicine so far. [USN: L4N2PK3WK]

Pfizer asked wholesalers and distributors on Thursday to stop the use and distribution of the tablets immediately.


Pfizer Inc said on Thursday it was recalling all lots of its anti-smoking treatment, Chantix, due to high levels of cancer-causing agents called nitrosamines in the pills.

Only two new coronaviruses have spread globally the past 2 decades: SARS-CoV, which caused an outbreak of severe acute respiratory syndrome (SARS) in 2,003 and SARS-CoV-2, the virus that causes COVID-19. But that may just be the tip of the iceberg of undetected infections with related viruses emerging from bats, a new paper claims. In a preprint published yesterday researchers estimate that an average of 400,000 people are likely infected with SARS-related coronaviruses every year, in spillovers that never grow into detectable outbreaks.

The researchers, including Peter Daszak from the EcoHealth Alliance and Linfa Wang from Duke-NUS Medical School in Singapore, created a detailed map of the habitats of 23 bat species known to harbor SARS-related coronaviruses, the group to which SARS-CoV and SARS-CoV-2 belong, and then overlaid it with data on where humans live to create a map of potential infection hot spots. They found that close to 500 million people live in areas where spillovers can occur, including northern India, Nepal, Myanmar, and most of Southeast Asia. The risk is highest in southern China, Vietnam, Cambodia, and on Java and other islands in Indonesia (see map, below).


Study pinpoints Asian regions that could spark the next coronavirus pandemic.

A new Rutgers study will examine how COVID-19 is affecting individuals in a number of cognitive-related areas, including memory loss, “brain fog,” and dementia.

“Many people who recover from mild or moderate COVID-19 notice slowed thinking or memory loss, and this motivated us to leverage our experience in studying cognitive issues related to Alzheimer’s disease, multiple sclerosis, and HIV to examine this phenomenon,” said Dr. William T. Hu, associate professor and chief of cognitive neurology at Rutgers Robert Wood Johnson Medical School and the Institute for Health, Health Care Policy, and Aging Research.

A leading cognitive neurologist and neuroscientist, Dr. Hu is spearheading the characterization of cognitive impairment following mild-to-moderate COVID-19 at Rutgers.

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern threatens the efficacy of existing vaccines and therapeutic antibodies and underscores the need for additional antibody-based tools that potently neutralize variants by targeting multiple sites of the spike protein. We isolated 216 monoclonal antibodies targeting SARS-CoV-2 from plasmablasts and memory B cells collected from patients with coronavirus disease 2019. The three most potent antibodies targeted distinct regions of the receptor-binding domain (RBD), and all three neutralized the SARS-CoV-2 Alpha and Beta variants. The crystal structure of the most potent antibody, CV503, revealed that it binds to the ridge region of SARS-CoV-2 RBD, competes with the angiotensin converting enzyme 2 receptor, and has limited contact with key variant residues K417, E484 and N501. We designed bispecific antibodies by combining non-overlapping specificities and identified five bispecific antibodies that inhibit SARS-CoV-2 infection at concentrations of less than 1 ng/mL. Through a distinct mode of action, three bispecific antibodies cross-linked adjacent spike proteins using dual N-terminal domain-RBD specificities. One bispecific antibody was greater than 100-fold more potent than a cocktail of its parent monoclonals in vitro and prevented clinical disease in a hamster model at a 2.5 mg/kg dose. Notably, two bispecific antibodies in our panel comparably neutralized the Alpha, Beta, Gamma and Delta variants and wild-type virus. Furthermore, a bispecific antibody that neutralized the Beta variant protected hamsters against SARS-CoV-2 expressing the E484K mutation. Thus, bispecific antibodies represent a promising next-generation countermeasure against SARS-CoV-2 variants of concern.


Bispecific antibodies targeting multiple regions of the SARS-CoV-2 spike protein comparably neutralize variants of concern and wild-type virus.

The first-in-human clinical trial for a candidate treatment for individuals living with human immunodeficiency virus type 1 is starting soon after its maker, Excision BioTherapeutics, today received an Investigational New Drug clearance from the U.S. Food and Drug Administration (FDA).

The FDA’s IND approval sets the stage for the very first Phase I/II trial to evaluate EBT-101 as a functional cure for chronic HIV based on the endpoints of safety, tolerability, and efficacy.

EBT-101, an in vivo, CRISPR-based drug that targets HIV proviral DNA, is a unique gene therapy that leverages CRISPR’s viral defense capability against bacteria. It uses an adeno-associated virus (AAV) to deliver a one-time treatment to functionally cure HIV infections. Preclinical studies show that it can excise HIV proviral DNA in multiple cell lines, including both human primary cells and multiple animal models and non-human primates.